Abstract

Imidazoles represent important bioactive scaffolds in medicinal chemistry. More than 2,500 structures are listed in drug discovery databases and over 3,000 patents have been claimed for imidazole-based structures. Recent imidazole pharmacophores have targeted various MAP kinases. p38 Mitogen-activated protein (MAP) kinase plays a central role in the signaling network responsible for the upregulation of proinflammatory cytokines like IL-1β and TNFα and offers, therefore, a valid target for small molecule anti-inflammatory drugs. 2-Sulfanylimidazole derivatives offer some advantages over prototype inhibitors (SB203580), e.g. lower cytochrom P450 interactions and better kinetic properties. We report here three novel regioselective and, at the same time, highly flexible synthetic approaches towards 1,4,5-trisubstituted 2-sulfanylimidazoles starting from different ethanone regioisomers allowing maximum variability of all substituents introduced. As a result, a variety of selective and highly potent p38 MAPK inhibitors were prepared and selected for further preclinical development. Synthesis of structurally diverse inhibitor candidates, p38 inhibition data, and selectivity profiling of some selected compounds are specified. Furthermore, the benefits of the useful, brief synthetic sequences are outlined and contrasted with already published multistep routes.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.